secwatch.observer — SEC 8-K summary
======================================

Issuer:     Quince Therapeutics, Inc. (QNCX)
CIK:        0001662774
Form:       8-K
Filed at:   2025-10-17T23:59:59+00:00
Accession:  0001193125-25-242514
Event type: other_material
Sentiment:  negative
Materiality: 0.55
Item codes: 7.01
LLM model:  deepseek-v4-flash:cloud@v2

Quince Therapeutics retracts false claim about IntraBio's Phase 2 study for NALL in A-T
--------------------------------------------------------------------------------

- Quince stated on Oct 2 Investor Day that IntraBio's NALL Phase 2 failed all endpoints in A-T; now retracts that statement.
- The statement was based on a different study (EJPN Article), not the IntraBio Phase 2 study; Quince removed it from materials.
- The EJPN Article found NALL failed to improve motor function significantly but improved some symptoms (e.g., nausea, constipation).
- Quince advises investors not to rely on the retracted statement; underlying facts did not support the original claim.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1662774/000119312525242514/0001193125-25-242514-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1662774/000119312525242514/d75404d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-242514

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer